Replies to post #2143 on Axim Biotechnologies Inc (AXIM)

[TexasMarvL]

It is refreshing to watch a facts-based video with no political agenda on vaccines and Immunity.

I think the short-term risk with #AXIM is that the CDC and FDA may never approve #ImmunoPass even though it is a great test and provides results in just 10 minutes without the need for a lab or nurse or doctor to TELL you your Immunity levels.

Maybe that is the main point. FDA, CDC, Big Pharma, and current political powers all want the focus on the vaccine solution. The goal is herd immunity, but the tactics are being ramped up for political (and Big Pharma roll-out to other countries) reasons. I still hope for #ImmunoPass approval in Europe or Israel or Australia.

I still like AXIM FDA approved Dry Eye Disease tests. I think we see a spike to $1 dollar or $1.50 in Q1 or Q2.

Good luck to all. I hope you have a diversified portfolio. Thanks.

[Devolution]

Thanks, Kaptain, that video was fabulous, and I would like to summarize my take on it and expand upon that.

Natural immunity (those who have had the virus) is the best immunity, as it results in the development of antibodies to 20 antigens on the virus, as well as the Memory B Cells (that make the antibody to those 20 antigens) and memory T-cells (that kill infected cells) that stay with you (probably for life) BUT the down-side of contracting COVID-19 are the systemic, long-term side effects associated with the virus.

Vaccination does not give as good of an immunity, as it only results in antibodies to 2 antigens on the virus, albeit the 2 most important antigens that result in antibodies for neutralizing the virus (and, of course, the development of memory B cells that know how to make antibodies to those 2 antigens), BUT has the advantage of preventing long term systemic side effects.

The vaccine provides 92% protection from getting infected by the virus whereas natural immunity provides 95% protection from getting (re)infected by the virus.

The important thing for AXIM: This pandemic is a learning experience, and as we move along the learning curve, the approach that society takes is EVOLVING. We (the United States) are just now getting to the step in the evolution of MANDATING vaccination. The next step will be the realization that Natural Immunity, developed after having contracted the virus, is just as good (actually better) at preventing a future infection, and that the best and easiest way (right now) of gauging any type of immunity (natural or vaccinated) is to look for ANTIBODIES to COVID-19.

Perfect timing for Immunopass, whose EUA will be coming soon, before the end of this year, probably before the Thanksgiving travel season, in my honest opinion.

The next step in the evolution will be the detection of those memory B-cells (that give long-term lasting immunity, as they remember how to make the antibodies once they have seen the virus' antigens, either the 2 antigens from the vaccine, or the 20 antigens from natural infection). Fortunately, this next step is probably years down the road and is extremely complicated to determine on a mass scale, so Immunopass will still be the fastest and easiest way to determin protection from the virus on a mass scale.

Yes, the DED test revenues will boost the pps, probably by the middle of next year, and will ensure that your investment in AXIM is "protected", but it is the massive boost in pps from the world-wide acceptance of Immunopass that has the potential to send AXIM into the stratosphere.